Advertisement
Advertisement

BMY

BMY logo

Bristol-Myers Squibb Co.

66.56
USD
Sponsored
-0.02
-0.03%
Aug 31, 13:01 UTC -4
Open

BMY Earnings Reports

Positive Surprise Ratio

BMY beat 37 of 42 last estimates.

88%

Next Report

Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$12.68B
/
$1.74
Implied change from Q2 26 (Revenue/ EPS)
-2.26%
/
-14.71%
Implied change from Q3 25 (Revenue/ EPS)
+3.75%
/
+6.75%

Bristol-Myers Squibb Co. earnings per share and revenue

On Jul 30, 2026, BMY reported earnings of 2.04 USD per share (EPS) for Q2 26, beating the estimate of 1.60 USD, resulting in a 27.20% surprise. Revenue reached 12.97 billion, compared to an expected 11.86 billion, with a 9.36% difference. The market reacted with a +2.79% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 1.74 USD, with revenue projected to reach 12.68 billion USD, implying an decrease of -14.71% EPS, and decrease of -2.26% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
logo
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
logo
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
logo
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-
Actual
-$0.35
Surprise
-
logo
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
logo
EVOGENE LTD.
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.14
Surprise
+49.16%
FAQ
For Q2 2026, Bristol-Myers Squibb Co. reported EPS of $2.04, beating estimates by 27.2%, and revenue of $12.97B, 9.36% above expectations.
The stock price moved up 2.79%, changed from $63.10 before the earnings release to $64.86 the day after.
The next earning report is scheduled for Oct 29, 2026.
Based on 10 analysts, Bristol-Myers Squibb Co. is expected to report EPS of $1.74 and revenue of $12.68B for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement